Assessing gut microbiome's role in predicting inflammatory bowel disease progression
Official title: Composition and Metabolic Activity of Gut Microbiota to Predict Early Inflammatory Bowel Disease Progression
Run by Pontificia Universidad Catolica de Chile · NCT06756100 · Data updated 2026-11-12
This study is trying to see if the types of bacteria in the gut can help predict how inflammatory bowel diseases like Crohn's disease and ulcerative colitis will progress in the first year after diagnosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | Pontificia Universidad Catolica de Chile Academic / other |
| Locations | 1 site (Santiago) |
| Status | Recruiting |
| Started | July 7, 2023 |
| Main results expected | April 2027 |
| Study ends | April 2027 |
| Registry record updated | January 1, 2025 |
| Trial ID | NCT06756100 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult patients experiencing gastrointestinal symptoms such as diarrhea, rectal bleeding, abdominal pain, or urgency for at least three weeks.
✕Probably not a fit
Patients with confirmed infectious diseases of the gastrointestinal tract will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate how the composition and function of gut microbiota can predict the progression of inflammatory bowel diseases (IBD), specifically Crohn's disease and ulcerative colitis, within the first year after diagnosis. It focuses on identifying biomarkers that could indicate the need for treatment escalation, which is crucial for improving patient outcomes and preventing complications. By analyzing fecal metabolites such as short-chain fatty acids and bile acids, the study seeks to establish a reliable method for guiding timely treatment decisions in IBD patients.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with inflammatory bowel disease.
How similar studies have gone: Other studies have indicated the potential of gut microbiota interactions in IBD progression, suggesting that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with with at least 3 weeks of gastrointestinal symptoms including diarrhea, rectal bleeding, abdominal pain, tenesmus or urgency Exclusion Criteria: * Confirmed infectious disease of the gastrointestinal tract
Where it's running
-
Pontificia Universidad Catolica of Chile
Santiago, Chile Recruiting
Study contacts
- Principal investigator: Cristian Hernández-Rocha, MD — Pontificia Universidad Catolica of chile
- Study coordinator: Cristian Hernández-Rocha, MD
- Email: caherna4@uc.cl
- Phone: 56-22-3543822
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Familial IBD Early Risk
This study tests whether clinical, environmental, and immune factors in first-degree relatives of people with Crohn’s disease or ulcerative colitis can predict who will develop IBD.
-
Biomarker Discovery and Validation Platform for Inflammatory Bowel Disease
Researchers are testing biomarker models to see if they can measure and predict inflammation and treatment response in people with Crohn's disease, ulcerative colitis, or related IBD.
-
Wearable data to spot IBD flareups in people with ulcerative colitis or Crohn's disease
This study tests whether heart‑rate variability from participants’ own wearables can help predict IBD flares.
-
Individualizing Anti-TNF Therapy in IBD
This study tests whether genetic markers can predict which anti-TNF–naïve IBD patients will respond to their first anti-TNF treatment.
-
LRG levels and IBD activity in European patients
This study will test whether Leucine-rich α2-glycoprotein (LRG) levels reflect disease activity in adults with Crohn’s or ulcerative colitis who are undergoing routine endoscopy in Europe.
-
CEDUR — German inflammatory bowel disease registry
This registry collects real-world health and treatment information from adults with Crohn's disease, ulcerative colitis, or indeterminate colitis in Germany to see how care, effectiveness, safety, and costs play out in routine practice.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.